Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance

Neuroendocrine prostate cancer (NEPC) is a highly aggressive histologic subtype of prostate cancer associated with a poor prognosis. Its incidence is expected to increase as castration-resistant disease emerges from the widespread use of potent androgen receptor-targeting therapies, such as abirater...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandya, Deep, Shah, Myra, Kaplan, Fuat, Martino, Candice, Levy, Gillian, Kazanjian, Mia, Batter, Stephen, Martignetti, John, Frank, Richard C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2021
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903888/
https://www.ncbi.nlm.nih.gov/pubmed/33608381
http://dx.doi.org/10.1101/mcs.a005801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903888/
https://www.ncbi.nlm.nih.gov/pubmed/33608381
http://dx.doi.org/10.1101/mcs.a005801

Ejemplares similares